[PDF]Concerning an Announcement by Kirin Holdings Company, Limited

On October 31, 2017 Today Kirin Holdings Company, Limited, parent company of Kyowa Hakko Kirin Co., Ltd. (hereinafter, "Kyowa Hakko Kirin") reported "Notice Regarding Termination of Joint Venture Agreement with Amgen Inc (Press release, Kyowa Hakko Kirin, OCT 31, 2017, View Source [SID1234521327])." However, this matter will not impact the business of Kyowa Hakko Kirin, and Kyowa Hakko Kirin will continue to develop, manufacture and sell pharmaceuticals licensed by Kirin-Amgen, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!